Edesa Biotech (EDSA) Competitors $2.10 -0.10 (-4.55%) (As of 09:59 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends EDSA vs. NAII, DRRX, MRKR, LGVN, LPCN, GOVX, LSB, EQ, TNXP, and BTAIShould you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include Natural Alternatives International (NAII), DURECT (DRRX), Marker Therapeutics (MRKR), Longeveron (LGVN), Lipocine (LPCN), GeoVax Labs (GOVX), Lakeshore Biopharma (LSB), Equillium (EQ), Tonix Pharmaceuticals (TNXP), and BioXcel Therapeutics (BTAI). These companies are all part of the "pharmaceutical products" industry. Edesa Biotech vs. Natural Alternatives International DURECT Marker Therapeutics Longeveron Lipocine GeoVax Labs Lakeshore Biopharma Equillium Tonix Pharmaceuticals BioXcel Therapeutics Natural Alternatives International (NASDAQ:NAII) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability. Does the MarketBeat Community believe in NAII or EDSA? Natural Alternatives International received 227 more outperform votes than Edesa Biotech when rated by MarketBeat users. However, 77.14% of users gave Edesa Biotech an outperform vote while only 75.37% of users gave Natural Alternatives International an outperform vote. CompanyUnderperformOutperformNatural Alternatives InternationalOutperform Votes25475.37% Underperform Votes8324.63% Edesa BiotechOutperform Votes2777.14% Underperform Votes822.86% Do analysts recommend NAII or EDSA? Edesa Biotech has a consensus target price of $21.00, suggesting a potential upside of 900.00%. Given Edesa Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Edesa Biotech is more favorable than Natural Alternatives International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Natural Alternatives International 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Edesa Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, NAII or EDSA? Natural Alternatives International has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, Edesa Biotech has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Does the media refer more to NAII or EDSA? In the previous week, Natural Alternatives International and Natural Alternatives International both had 1 articles in the media. Natural Alternatives International's average media sentiment score of 0.00 equaled Edesa Biotech'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natural Alternatives International 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Edesa Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in NAII or EDSA? 32.4% of Natural Alternatives International shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 20.9% of Natural Alternatives International shares are owned by insiders. Comparatively, 25.0% of Edesa Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is NAII or EDSA more profitable? Edesa Biotech has a net margin of 0.00% compared to Natural Alternatives International's net margin of -7.53%. Natural Alternatives International's return on equity of -10.23% beat Edesa Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Natural Alternatives International-7.53% -10.23% -5.38% Edesa Biotech N/A -137.95%-97.48% Which has stronger valuation & earnings, NAII or EDSA? Natural Alternatives International has higher revenue and earnings than Edesa Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNatural Alternatives International$113.80M0.24-$7.22M-$1.44-3.03Edesa BiotechN/AN/A-$8.37MN/AN/A SummaryEdesa Biotech beats Natural Alternatives International on 7 of the 13 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Edesa Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDSA vs. The Competition Export to ExcelMetricEdesa BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.15M$6.44B$5.05B$8.82BDividend YieldN/A8.11%5.17%4.07%P/E RatioN/A10.69125.6917.78Price / SalesN/A243.731,179.7874.25Price / CashN/A22.1633.7732.53Price / Book0.945.474.684.68Net Income-$8.37M$153.61M$119.54M$226.08M7 Day PerformanceN/A-4.32%-2.46%-2.04%1 Month Performance-45.81%-8.61%-4.08%0.06%1 Year Performance-27.87%28.79%29.82%24.60% Edesa Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDSAEdesa Biotech3.1435 of 5 stars$2.10-4.5%$21.00+900.0%-27.9%$6.83MN/A0.0020Gap DownNAIINatural Alternatives International0.3468 of 5 stars$4.36-1.4%N/A-27.8%$27.03M$113.80M0.00290Analyst ForecastNews CoverageDRRXDURECT3.0843 of 5 stars$0.86-4.8%$5.00+481.3%+39.5%$26.70M$8.55M0.0080Analyst ForecastAnalyst RevisionNews CoverageGap DownMRKRMarker Therapeutics3.8639 of 5 stars$2.98-6.3%$19.00+537.6%+17.8%$26.58M$3.31M0.0060LGVNLongeveron2.3938 of 5 stars$1.83-1.1%$8.00+337.2%-90.4%$26.28M$710,000.000.0023LPCNLipocine2.0423 of 5 stars$4.71flat$10.00+112.3%+96.3%$25.20M$500,000.00-6.7110GOVXGeoVax Labs3.164 of 5 stars$2.64+1.1%$13.25+401.9%-67.4%$24.92M$80,000.000.0017Gap DownLSBLakeshore Biopharma0.2075 of 5 stars$2.66+1.5%N/AN/A$24.77M$80.82M0.00773Gap DownEQEquillium3.1992 of 5 stars$0.69-3.6%$5.00+622.6%+43.6%$24.51M$36.08M0.0040Analyst RevisionGap DownTNXPTonix Pharmaceuticals2.9676 of 5 stars$0.18-6.1%$53.50+29,888.8%-98.8%$24.49M$7.77M0.00103Analyst ForecastGap DownBTAIBioXcel Therapeutics4.5174 of 5 stars$0.57-3.4%$5.00+780.3%-84.6%$24.28M$1.38M0.0090Gap Down Related Companies and Tools Related Companies NAII Competitors DRRX Competitors MRKR Competitors LGVN Competitors LPCN Competitors GOVX Competitors LSB Competitors EQ Competitors TNXP Competitors BTAI Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EDSA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edesa Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edesa Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
